News

Gastric Inhibitory Polypeptide Receptor Research Report: Competitor, Under Development Projects, Mergers and Acquisition, Discontinued Projects and more

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) – Glucose-dependent insulinotropic polypeptide receptor (GIPR) is a transmembrane protein in humans which is encoded by the GIPR gene. GIPR is expressed on pancreatic beta-cells which lead to activation and release of insulin. The transcription of this protein is positively controlled by glucose molecules. GIPR is expressed in higher levels when glucose is in higher concentration. The ligand which binds to GIPR is glucose-dependent insulinotropic polypeptide (GIP) also known as gastric inhibitory polypeptide. Glucose-dependent insulinotropic polypeptide is released from the duodenum and small intestine.

Report Source: https://www.themarketreports.com/report/gastric-inhibitory-polypeptide-receptor-glucose-dependent-insulinotropic-polypeptide-receptor-or-gipr-pipeline-review-h1

Scope

  • The report provides a snapshot of the global therapeutic landscape for Gastric Inhibitory Polypeptide Receptor
  • The report reviews Gastric Inhibitory Polypeptide Receptor targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Gastric Inhibitory Polypeptide Receptor targeted therapeutics and enlists all their major and minor projects
  • The report assesses Gastric Inhibitory Polypeptide Receptor targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects

Purchase this report at: https://www.themarketreports.com/report/buy-now/1466928

Reasons To Buy

  • Identify and understand the targeted therapy areas and indications for Gastric Inhibitory Polypeptide Receptor
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Gastric Inhibitory Polypeptide Receptor development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

  • Antag Therapeutics ApS
  • Carmot Therapeutics Inc
  • Eli Lilly and Co
  • Hanmi Pharmaceuticals Co Ltd
  • Longevity Biotech Inc
  • Novo Nordisk AS
  • Sanofi
  • Zealand Pharma AS

Got a question; ask us at: https://www.themarketreports.com/report/ask-your-query/1466928